Evidence map›Paper›PMID 42877652›Full record

ArticleArchives of medical science : AMS2026

COVID-19 disease: novel clinical manifestations and therapeutic exploration.

Chun Liu, Qiang Huang, PingXi Wang, HuaPing Wu, ShuKai Deng, Dan Liu, ChunFeng Xiang, Qiang Gao, FanWei Zeng, XiangDe Zheng

Abstract read
In one paragraph

Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chun LiuDepartment of Critical Care Medicine, Dazhou Central Hospital, Sichuan Province, China.
Qiang HuangDepartment of Critical Care Medicine, Wenjiang District People's Hospital, Chengdu-Sichuan Province, China.
PingXi WangScience and Education-Dazhou Central Hospital, Sichuan Province, China.
HuaPing WuScience and Education-Dazhou Central Hospital, Sichuan Province, China.
ShuKai DengDepartment of Respiratory Medicine, Affiliated Hospital of Southwest Medical University, Sichuan Province, China.
Dan LiuDepartment of Respiratory Medicine, Affiliated Hospital of Southwest Medical University, Sichuan Province, China.
ChunFeng XiangImaging Center, Dazhou Central Hospital, Sichuan Province, China.
Qiang GaoDepartment of Critical Care Medicine, Dazhou Central Hospital, Sichuan Province, China.
FanWei ZengScience and Education-Dazhou Central Hospital, Sichuan Province, China.
XiangDe ZhengDepartment of Critical Care Medicine, Dazhou Central Hospital, Sichuan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study aims to provide further clarifications on some new clinical characteristics of COVID-19 recently discovered by our research group. Material and methods: In this single-centred, retrospective study, we collected all confirmed cases of COVID-19 diagnosed in Dazhou, Sichuan, China from January 23 to February 25, 2020. All the cases were either imported from Wuhan or transmitted in family clusters. We analysed general information on all patients. Meanwhile, the contents of lactic acid, fibrinogen C (Fib-C), and D-dimer in the serum of patients were detected. Results: The study included 37 patients diagnosed as having COVID-19, the average age of the patients was 45.76 ±13.1 years. The average positive time of nucleic acid in pharyngeal swabs was 20.65 ±6.7 days. A total of 4 (10.8%) patients were asymptomatic. On serological examination, 33 (89.1%) patients had increased lactic acid, 17 patients had increased Fib-C, and 5 patients had increased D-dimer. Of all patients, 29 were positive for COVID-19-specific antibodies. We also detected COVID-19 nucleic acid in faecal specimens from 4 patients. Klebsiella pneumoniae was found in the sputum of 1 patient. A total of 4 patients received psychological intervention. Lopinavir/ritonavir and Abidol may not be effective in treating COVID-19. Conclusions: In the serum of most COVID-19-infected patients, lactic acid was higher than normal, and COVID-19-specific antibody was positive. Fib-C and D-dimer in the serum of some infected patients increased. Lopinavir/ritonavir and Abidol have little effect on shortening the positive time of viral nucleic acid in patients.

Indexed as

AbidolCOVID-19D-dimerFib-Clactic acidlopinavir/ritonavirSARS-CoV-2

Identifiers

PMID42877652
PMCPMC13663634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.